UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin sompared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;353:837-53.
2.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352:854-65.
3.
HolmanRRPaulSKBethelMA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med2008;359: 1577-89.
GaedePVedelPLarsenN. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med2003;348:383-93.
6.
GaedePLund-AndersenHParvingHHPedersenO. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008;358:580-91.
7.
MalmbergKRydenLEfendicS. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study):effects on mortality at 1 year. J Am Coll Cardiol1995;26: 57-65.
8.
MalmbergKRydenLWedelH. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2):effects on mortality and morbidity. Eur Heart J2005;26:650-61.
9.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008;358:2545-59.
10.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008;358:560-72.
11.
DuckworthWAbrairaCMoritzT. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med2009;360:129-39.
12.
SkylerJSBergenstalRBonowRO. Intensive glycemic control and the prevention of cardiovascular events:implications of the ACCORD, ADVANCE and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation2009;119:351-7.
13.
Del PratoS. Megatrials in type 2 diabetes. From excitement to frustration?Diabetologia2009;52:1219-26.
14.
RayKKSeshasaiSRKWijesuriyaS. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus:a meta-analysis of randomised controlled trials. Lancet2009;373:1765-72.
15.
CurrieCJPetersJRTynanA. Survival as a function of HbA1c in people with type 2 diabetes:a retrospective cohort study. Lancet2010;375:481-9
16.
Standards of medical care in diabetes – 2012. Diabetes Care2012;35:suppl 1, S11-63.
17.
InzucchiSEBergenstalRMBuseJB. Management of hyperglycaemia in type 2 diabetes:a patient-centred approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia2012;55:1577-96 and Diabetes Care epub ahead of print.
18.
HandelsmanYBlondeLBloomgardenZT. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Comprehensive Diabetes Mellitus Care Plan. Endocrine Pract2011;17:suppl 2, 1-63. https://www.aace.com/files/dm-guidelines-ccp.pdf
19.
IDF clinical guidelines taskforce. Global guideline for type 2 diabetes. International Diabetes Federation, Brussels, 2005 pp79.
20.
BaileyCJBlondeLDel PratoS. What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diab Vasc Dis Res2009;6:283-7.
21.
The University Group Diabetes Program. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. Diabetes1970;19:suppl2, 747-830.
VergesBBonnardCRenardE. Beyond glucose lowering:glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab2011;37:477-88.
24.
The ORIGIN trial investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med2012; in press DOI.10.1056/NEJMoa120385810.1056/NEJMoa1203858.
